Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Table of Contents

In This Issue

  • In This Issue
    In This Issue
    Cancer Discov March 1 2019 9 (3) 305-308; DOI:10.1158/2159-8290.CD-ITI9-3

In the Spotlight

  • In the Spotlight
    Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL
    Shanmugapriya Thangavadivel and John C. Byrd
    Cancer Discov March 1 2019 9 (3) 320-322; DOI:10.1158/2159-8290.CD-19-0029

  • In the Spotlight
    Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor–Positive Breast Cancer
    Joshua Z. Drago, Sarat Chandarlapaty and Komal Jhaveri
    Cancer Discov March 1 2019 9 (3) 323-325; DOI:10.1158/2159-8290.CD-19-0050

  • In the Spotlight
    Metabolism Drives Carcinogenesis and Maintenance of Pancreatic Tumors
    Christopher J. Halbrook, Barbara S. Nelson and Costas A. Lyssiotis
    Cancer Discov March 1 2019 9 (3) 326-328; DOI:10.1158/2159-8290.CD-19-0034

Review

  • Review | AuthorChoice
    Targeting Alterations in the RAF–MEK Pathway
    Rona Yaeger and Ryan B. Corcoran
    Cancer Discov March 1 2019 9 (3) 329-341; DOI:10.1158/2159-8290.CD-18-1321

Research Brief

  • Research Brief | AuthorChoice
    Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
    Piers Blombery, Mary Ann Anderson, Jia-nan Gong, Rachel Thijssen, Richard W. Birkinshaw, Ella R. Thompson, Charis E. Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E. Lew, Ian J. Majewski, Daniel H.D. Gray, David A. Westerman, Constantine S. Tam, John F. Seymour, Peter E. Czabotar, David C.S. Huang and Andrew W. Roberts
    Cancer Discov March 1 2019 9 (3) 342-353; DOI:10.1158/2159-8290.CD-18-1119

    The recurrent BCL2 Gly101Val point mutation decreases binding to the BCL2 inhibitor venetoclax and mediates acquired resistance in patients with chronic lymphocytic leukemia.

Research Articles

  • Research Articles | AuthorChoice
    A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
    Sheau W. Lok, James R. Whittle, François Vaillant, Charis E. Teh, Louisa L. Lo, Antonia N. Policheni, Alice R.T. Bergin, Jayesh Desai, Sarah Ftouni, Luke C. Gandolfo, Danny Liew, He K. Liu, G. Bruce Mann, Kate Moodie, Anand Murugasu, Bhupinder Pal, Andrew W. Roberts, Mark A. Rosenthal, Kylie Shackleton, Maria João Silva, Zhen R. Siow, Gordon K. Smyth, Leanne Taylor, Avraham Travers, Belinda Yeo, Miriam M. Yeung, Andjelija Zivanovic Bujak, Sarah-Jane Dawson, Daniel H.D. Gray, Jane E. Visvader and Geoffrey J. Lindeman
    Cancer Discov March 1 2019 9 (3) 354-369; DOI:10.1158/2159-8290.CD-18-1151

    Combined treatment with tamoxifen and the BCL2 inhibitor venetoclax is safe and shows clinical activity in patients with ER+ and BCL2+ metastatic breast cancer.

  • Research Articles | AuthorChoice
    Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
    Naval Daver, Guillermo Garcia-Manero, Sreyashi Basu, Prajwal C. Boddu, Mansour Alfayez, Jorge E. Cortes, Marina Konopleva, Farhad Ravandi-Kashani, Elias Jabbour, Tapan Kadia, Graciela M. Nogueras-Gonzalez, Jing Ning, Naveen Pemmaraju, Courtney D. DiNardo, Michael Andreeff, Sherry A. Pierce, Tauna Gordon, Steven M. Kornblau, Wilmer Flores, Zainab Alhamal, Carlos Bueso-Ramos, Jeffrey L. Jorgensen, Keyur P. Patel, Jorge Blando, James P. Allison, Padmanee Sharma and Hagop Kantarjian
    Cancer Discov March 1 2019 9 (3) 370-383; DOI:10.1158/2159-8290.CD-18-0774

    The addition of immune checkpoint blockade to hypomethylating therapy is safe and effective in patients with acute myeloid leukemia.

  • Research Articles | AuthorChoice
    A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
    Alexander Drilon, Siqing Fu, Manish R. Patel, Marwan Fakih, Ding Wang, Anthony J. Olszanski, Daniel Morgensztern, Stephen V. Liu, Byoung Chul Cho, Lyudmila Bazhenova, Cristina P. Rodriguez, Robert C. Doebele, Antoinette Wozniak, Karen L. Reckamp, Tara Seery, Petros Nikolinakos, Zheyi Hu, Jennifer W. Oliver, Denise Trone, Katherine McArthur, Rupal Patel, Pratik S. Multani and Myung-Ju Ahn
    Cancer Discov March 1 2019 9 (3) 384-395; DOI:10.1158/2159-8290.CD-18-0839

    The VEGFR-sparing multikinase RET inhibitor RXDX-105 exhibits antitumor activity and inhibition of RET in patients with non-KIF5B–RET non–small cell lung cancer.

  • Research Articles | AuthorChoice
    ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
    Rani Ojha, Nektaria M. Leli, Angelique Onorati, Shengfu Piao, Ioannis I. Verginadis, Feven Tameire, Vito W. Rebecca, Cynthia I. Chude, Sengottuvelan Murugan, Colin Fennelly, Estela Noguera-Ortega, Charleen T. Chu, Shujing Liu, Xiaowei Xu, Clemens Krepler, Min Xiao, Wei Xu, Zhi Wei, Dennie T. Frederick, Genevieve Boland, Tara C. Mitchell, Giorgos C. Karakousis, Lynn M. Schuchter, Keith T. Flaherty, Gao Zhang, Meenhard Herlyn, Constantinos Koumenis and Ravi K. Amaravadi
    Cancer Discov March 1 2019 9 (3) 396-415; DOI:10.1158/2159-8290.CD-18-0348

    Combined BRAF and MEK inhibition induces ER translocation of MAPK pathway components, followed by ERK reactivation and induction of autophagy.

  • Research Articles
    Acetyl-CoA Metabolism Supports Multistep Pancreatic Tumorigenesis
    Alessandro Carrer, Sophie Trefely, Steven Zhao, Sydney L. Campbell, Robert J. Norgard, Kollin C. Schultz, Simone Sidoli, Joshua L.D. Parris, Hayley C. Affronti, Sharanya Sivanand, Shaun Egolf, Yogev Sela, Marco Trizzino, Alessandro Gardini, Benjamin A. Garcia, Nathaniel W. Snyder, Ben Z. Stanger and Kathryn E. Wellen
    Cancer Discov March 1 2019 9 (3) 416-435; DOI:10.1158/2159-8290.CD-18-0567

    Increased utilization of acetyl-CoA promotes plasticity in Kras-mutant pancreatic cells and renders PDAC sensitive to inhibitors of the BET family of proteins and HMG-CoA reductase.

  • Research Articles
    Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL
    Agnieszka A. Wendorff, S. Aidan Quinn, Marissa Rashkovan, Chioma J. Madubata, Alberto Ambesi-Impiombato, Mark R. Litzow, Martin S. Tallman, Elisabeth Paietta, Maddalena Paganin, Giuseppe Basso, Julie M. Gastier-Foster, Mignon L. Loh, Raul Rabadan, Pieter Van Vlierberghe and Adolfo A. Ferrando
    Cancer Discov March 1 2019 9 (3) 436-451; DOI:10.1158/2159-8290.CD-18-1005

    PHF6 loss-of-function is an early event in T-ALL development that facilitates leukemic initiation by promoting HSC expansion and selfrenewal.

News in Brief

  • News in Brief
    People
    Cancer Discov March 1 2019 9 (3) 310-310; DOI:10.1158/2159-8290.CD-NB2019-007

  • News in Brief
    FDA to Consider Real-World Evidence
    Cancer Discov March 1 2019 9 (3) 310-310; DOI:10.1158/2159-8290.CD-NB2019-005

  • News in Brief
    AIs Recommended for Breast Cancer Prevention
    Cancer Discov March 1 2019 9 (3) 311-311; DOI:10.1158/2159-8290.CD-NB2019-013

  • News in Brief
    BRCA Exchange Launches
    Cancer Discov March 1 2019 9 (3) 311-312; DOI:10.1158/2159-8290.CD-NB2019-008

  • News in Brief
    Experts Question Recent Pharma Acquisitions
    Cancer Discov March 1 2019 9 (3) 312-312; DOI:10.1158/2159-8290.CD-NB2019-009

  • News in Brief
    Olaratumab for STS Disappoints in Phase III
    Cancer Discov March 1 2019 9 (3) 312-313; DOI:10.1158/2159-8290.CD-NB2019-011

  • News in Brief
    Desmoid Tumors Respond to Sorafenib
    Cancer Discov March 1 2019 9 (3) 313-313; DOI:10.1158/2159-8290.CD-NB2019-004

  • News in Brief
    Hypoxic Tumors Share Genomic Instability
    Cancer Discov March 1 2019 9 (3) 314-314; DOI:10.1158/2159-8290.CD-NB2019-012

  • News in Brief
    Noted
    Cancer Discov March 1 2019 9 (3) 314-314; DOI:10.1158/2159-8290.CD-NB2019-006

Research Watch

  • Autophagy

    • Research Watch
      Autophagy Prevents Bypass of Replicative Crisis
      Cancer Discov March 1 2019 9 (3) 317-317; DOI:10.1158/2159-8290.CD-RW2019-014

  • Clinical Trials

    • Research Watch
      Ibrutinib plus Palbociclib Has Efficacy in Mantle Cell Lymphoma
      Cancer Discov March 1 2019 9 (3) 318-318; DOI:10.1158/2159-8290.CD-RW2019-016

  • Drug Design

    • Research Watch
      De Novo Cytokine Mimics Have Improved Therapeutic Properties
      Cancer Discov March 1 2019 9 (3) 319-319; DOI:10.1158/2159-8290.CD-RW2019-008

  • Epigenetics

    • Research Watch
      GADD45A Recruits Demethylation Proteins to CpG Island Promoters
      Cancer Discov March 1 2019 9 (3) 315-315; DOI:10.1158/2159-8290.CD-RW2019-009

  • Gliomas

    • Research Watch
      ctDNA Profiling of Cerebrospinal Fluid Characterizes Glioma Evolution
      Cancer Discov March 1 2019 9 (3) 318-318; DOI:10.1158/2159-8290.CD-RW2019-013

  • Immunology

    • Research Watch
      Antitumor PD-1− CD8+ T-cell Subsets Expand upon Anti–PD-1/TIM3 Therapy
      Cancer Discov March 1 2019 9 (3) 315-315; DOI:10.1158/2159-8290.CD-RW2019-007

  • Leukemia

    • Research Watch
      NPM1 Mutations Create a Targetable Shared Neoantigen in AML
      Cancer Discov March 1 2019 9 (3) 319-319; DOI:10.1158/2159-8290.CD-RW2019-012

  • Metabolism

    • Research Watch
      Central Carbon Metabolism Regulates Macrophage Antitumor Activity
      Cancer Discov March 1 2019 9 (3) 316-316; DOI:10.1158/2159-8290.CD-RW2019-015

  • Metastasis

    • Research Watch
      B Cell–Derived Antibodies Promote Lymph Node Metastasis in Breast Cancer
      Cancer Discov March 1 2019 9 (3) 316-316; DOI:10.1158/2159-8290.CD-RW2019-010

  • Oncogenes

    • Research Watch
      MYC-Mediated Translation of PD-L1 Promotes Liver Cancer Immune Escape
      Cancer Discov March 1 2019 9 (3) 317-317; DOI:10.1158/2159-8290.CD-RW2019-011

Back to top
PreviousNext
Cancer Discovery: 9 (3)
March 2019
Volume 9, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • In This Issue
  • In the Spotlight
  • Review
  • Research Brief
  • Research Articles
  • News in Brief
  • Research Watch
    • Autophagy
    • Clinical Trials
    • Drug Design
    • Epigenetics
    • Gliomas
    • Immunology
    • Leukemia
    • Metabolism
    • Metastasis
    • Oncogenes
Advertisement
  • Most Cited
  • Most Read
Loading
  • The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
  • Macrophages Regulate Response to Chemotherapy
  • Core Resistance Mechanisms and Genetic Evolution of Melanoma under BRAF Inhibitor Selection
  • Novel Mutant-Selective EGFR Inhibitor Overcomes Drug Resistance
  • EGFR Mediates RAF Inhibitor Resistance in BRAF-Mutant Colorectal Cancer
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement